ASCP MLS Exam Prep: Free Practice Questions, Study Map, and 4-Week Plan
Start with 33 original ASCP MLS practice questions spread across all seven areas of the ASCP BOC content guideline (revised June 9, 2026). Then let your misses pick your first study sessions.
Original, unofficial practice written by Castleport Test Prep. These are not ASCP exam questions.
Practice questions
Hematology
Q1 · Corrected WBC count
(MLS-HEM-01)
An automated WBC count is 15.0 × 10³/µL and has not been corrected for included nucleated RBCs (nRBCs). The differential shows 25 nRBCs per 100 WBCs. What is the corrected WBC count?
Answer: B. 12.0 × 10³/µL — Corrected WBC = uncorrected WBC × 100 / (100 + nRBCs per 100 WBC) = 15.0 × 100/125 = 12.0 × 10³/µL. When nRBCs are included in the uncorrected count, they falsely increase the WBC result. A subtracts 25% of the count, which overcorrects because the nRBCs were counted inside the total. C multiplies instead of dividing. D leaves the included nRBCs uncorrected. Do not apply this correction again if the analyzer has already excluded nRBCs.
Source: ASCP BOC MLS content guideline, p. 14: required calculations; Sysmex, nRBC interference and WBC correction.
Q2 · RBC indices
(MLS-HEM-02)
RBC 4.00 × 10⁶/µL, hemoglobin 9.0 g/dL, hematocrit 30%. Which description fits?
Answer: D. Microcytic, hypochromic — MCV = Hct × 10 / RBC = 300/4.00 = 75 fL, below ASCP's 76–100 fL exam range. MCHC = Hgb / Hct × 100 = 9.0/30 × 100 = 30 g/dL, below 32–36 g/dL. Small and pale means microcytic, hypochromic. A and B ignore the low MCV; C ignores the low MCHC. In a real workup, iron studies such as ferritin would help separate iron deficiency from thalassemia trait.
Source: ASCP BOC MLS content guideline, pp. 14–15: calculations and exam ranges; CDC/NHANES CBC procedure, pp. 3–4: indices and absolute counts; Sysmex, RBC counting technology: indices, pp. 6 and 8; Lifeblood, investigating iron deficiency: ferritin and interpretation table.
Q3 · Mixing studies
(MLS-HEM-03)
PT is normal and aPTT is prolonged. A 1:1 mix with normal pooled plasma corrects immediately, but after 1–2 hours at 37 °C the mixed aPTT is prolonged again. Incubation controls are acceptable, and anticoagulant interference has been excluded. What is the most likely cause?
Answer: A. A time-dependent inhibitor, such as an acquired factor VIII inhibitor — Correction that disappears after incubation suggests a time- and temperature-dependent inhibitor; acquired factor VIII inhibitors can behave this way. A simple deficiency (B) stays corrected after incubation. Lupus anticoagulant (C) usually fails to correct even on the immediate mix. Factor VII deficiency (D) prolongs the PT, not the aPTT. Specific factor and inhibitor assays are needed to identify the cause.
Source: Labcorp, aPTT Mixing Studies: limitations and interpretation.
Q4 · Cytochemistry
(MLS-HEM-04)
A peripheral smear shows many blasts, several containing Auer rods. Which cytochemical stain would you expect to be positive in these blasts?
Answer: C. Myeloperoxidase (MPO) — Auer rods are fused primary granules in myeloid blasts, so they point to acute myeloid leukemia and stain MPO-positive. TRAP (A) is associated with hairy cell leukemia. Prussian blue (B) stains iron, such as in ringed sideroblasts. Kleihauer-Betke (D) detects fetal hemoglobin in red cells.
Source: ASH Image Bank, Auer rods and MPO; ASH Image Bank, hairy cell leukemia and TRAP; ASH Image Bank, Prussian blue and ringed sideroblasts; University of Chicago, postpartum RhIG evaluation: calculation rule.
Q5 · DIC vs TTP
(MLS-HEM-05)
A septic patient with no recent heparin exposure has platelets 40 × 10³/µL, schistocytes, prolonged PT and aPTT, fibrinogen 90 mg/dL, and a markedly elevated D-dimer. This picture is most consistent with:
Answer: C. Disseminated intravascular coagulation (DIC) — DIC consumes platelets and clotting factors (typically prolonged PT/aPTT and low fibrinogen) while fibrinolysis drives D-dimer up; sepsis is a classic trigger. Not every DIC patient shows every abnormality, but this full set is the textbook pattern. TTP (A) also has schistocytes and low platelets, but the coagulation profile is typically normal. ITP (B) typically causes isolated thrombocytopenia, without this schistocyte and coagulation-factor-consumption pattern. HIT (D) is less likely without recent heparin exposure; the overall pattern directly supports sepsis-associated DIC.
Source: Labcorp, DIC profile: additional information; TMA consensus, Table 1: laboratory patterns; ASH HIT pocket guide, p. 2: exposure and timing; Diagnostic approach to microangiopathic hemolytic disorders, §3.2.
Blood Banking
Q6 · ABO typing
(MLS-BB-01)
An adult's ABO testing gives these results, with acceptable controls: patient red cells + anti-A = 4+; patient red cells + anti-B = 0; patient plasma + A₁ cells = 0; patient plasma + B cells = 4+. Which ABO group fits the whole pattern?
Answer: B. A — Forward typing tests the red cells for antigens; reverse typing tests the plasma for antibodies. The cells react with anti-A (A antigen present), and the plasma agglutinates B cells (anti-B present), so both halves agree: group A. Group O (A) shows no forward reactions and agglutinates both reverse cells. Group B (C) is the mirror image of this pattern. Group AB (D) reacts with both forward reagents and neither reverse cell. ABO typing alone doesn't tell you Rh type or full compatibility.
Source: Canadian Blood Services, Pre-transfusion testing: ABO typing, Table 1.
Q7 · Delayed hemolytic reaction
(MLS-BB-02)
Seven days after a 2-unit RBC transfusion, a patient's hemoglobin drops and bilirubin rises. The pretransfusion antibody screen was negative. Today the DAT is positive (IgG), and anti-Jkᵃ is identified in the eluate. What is the best explanation?
Answer: D. Delayed hemolytic reaction from an anamnestic Kidd antibody — Kidd antibodies are known for dropping below detectable levels and then returning quickly after re-exposure, a classic cause of delayed hemolytic reactions days later. ABO errors (A) hemolyze within minutes to hours. TRALI (B) is a respiratory reaction within about 6 hours. A febrile reaction (C) doesn't produce a positive DAT with a specific antibody in the eluate.
Source: Lifeblood, delayed haemolytic transfusion reactions; AABB/ARC/ABC/ASBP Circular: reactions and component storage.
Q8 · Enzyme-treated panels
(MLS-BB-03)
An antibody reacts at the anti-human globulin (AHG) phase with untreated panel cells but shows no reactivity when the same cells are tested at AHG after validated ficin treatment. Which specificity is most likely?
Answer: B. Anti-Fyᵃ — Ficin and papain destroy Duffy (Fyᵃ, Fyᵇ), M, and N antigens (S is affected variably), so their reactivity disappears on enzyme-treated cells. Rh (A) and Kidd (C) reactivity is typically enhanced by enzymes. Kell antigens (D) survive ficin; they're destroyed by thiol reagents such as DTT.
Source: FDA-hosted panel instructions, pp. 1 and 3: ficin effects; AABB Bulletin 16-02, p. 3: DTT destroys Kell antigens.
Q9 · Rh immune globulin dose
(MLS-BB-04)
For a postpartum Rh immune globulin (RhIG) dose calculation in an unsensitized RhD-negative patient with an RhD-positive newborn, a Kleihauer-Betke stain shows 1.5% fetal cells. Use an assumed maternal blood volume of 5,000 mL and the laboratory rule of rounding the calculated vial count to the nearest whole number (0.5 rounds up), then adding one vial. How many 300 µg vials does this calculation give?
Answer: A. 4 — Fetal bleed = 1.5% × 5,000 mL = 75 mL of whole blood. One 300 µg vial covers about 30 mL of fetal whole blood: 75/30 = 2.5 vials. Round per the stated laboratory rule (0.5 or above rounds up, giving 3), then add one vial as a safety margin: 4. B and C skip the rounding and/or the extra vial. D adds the extra vial twice.
Source: University of Chicago, postpartum RhIG evaluation: calculation rule.
Q10 · Component storage
(MLS-BB-05)
Which storage condition is correct?
Answer: C. Conventional room-temperature platelets: 20–24 °C with continuous gentle agitation — Conventional room-temperature platelet components are kept at 20–24 °C with continuous gentle agitation to preserve function. Liquid RBCs are refrigerated at 1–6 °C, so A and D are both wrong. Frozen plasma (B) is stored at −18 °C or colder, not refrigerated.
Source: 21 CFR 640.25(a), platelet storage; AABB/ARC/ABC/ASBP Circular: reactions and component storage.
Q11 · Universal plasma
(MLS-BB-06)
Plasma of which ABO group is compatible with recipients of all ABO groups?
Answer: B. Group AB — Group AB plasma contains neither anti-A nor anti-B, so it is ABO-compatible with recipients of all ABO groups. Group O plasma (A) contains both antibodies, and group A (C) and group B (D) plasma each contain one. For ABO compatibility, remember the flip: group O is the universal red cell choice; group AB is the universal plasma donor.
Source: Lifeblood, component compatibility: red cells and plasma.
Chemistry
Q12 · Anion gap
(MLS-CHM-01)
Na⁺ 138 mmol/L, Cl⁻ 98 mmol/L, HCO₃⁻ 12 mmol/L, glucose 520 mg/dL, urine ketones positive. What is the anion gap, and what does it suggest?
Answer: D. 28 mmol/L; high anion gap metabolic acidosis — Anion gap = Na⁺ − (Cl⁻ + HCO₃⁻) = 138 − 110 = 28 mmol/L, well above the usual reference interval. With hyperglycemia and ketones, this fits diabetic ketoacidosis, where ketoacids are the unmeasured anions. A gets the number right but the interpretation wrong. B and C are arithmetic errors.
Source: 2024 hyperglycemic-crises consensus, §3: anion gap and DKA.
Q13 · Friedewald LDL
(MLS-CHM-02)
Total cholesterol 240 mg/dL, HDL 40 mg/dL, triglycerides 200 mg/dL. What is the calculated LDL cholesterol using the Friedewald equation?
Answer: B. 160 mg/dL — Friedewald: LDL = TC − HDL − TG/5 = 240 − 40 − 40 = 160 mg/dL. TG/5 estimates VLDL cholesterol in mg/dL. A incorrectly divides triglycerides by 2.5 instead of 5. C divides by 10. D is TC − HDL, which is non-HDL cholesterol, not LDL. The equation isn't valid when triglycerides are 400 mg/dL or higher.
Source: CDC/NHANES, calculated LDL: Friedewald equation and limits.
Q14 · Osmolal gap
(MLS-CHM-03)
Na⁺ 140 mmol/L, glucose 90 mg/dL, BUN 14 mg/dL, measured osmolality 330 mOsm/kg. Using calculated osmolality = 2Na + glucose/18 + BUN/2.8, which statement is correct?
Answer: C. Calculated 290; osmolal gap 40, suggesting an unmeasured osmole such as ethylene glycol or methanol — Calculated osmolality = 2(Na) + glucose/18 + BUN/2.8 = 280 + 5 + 5 = 290 mOsm/kg. Gap = 330 − 290 = 40, pointing to unmeasured osmotically active substances such as ethanol, methanol, or ethylene glycol. A assumes no gap. B drops glucose and BUN from the formula and misreads the cause. D miscalculates, and the sodium here is normal.
Source: Choy et al., osmolal-gap formulas and interpretation; University of Iowa, osmolal-gap interpretation.
Q15 · Blood gas interpretation
(MLS-CHM-04)
Arterial pH 7.25, pCO₂ 60 mm Hg, HCO₃⁻ 26 mmol/L. What is the interpretation?
Answer: A. Acute respiratory acidosis — Low pH with high pCO₂ is respiratory acidosis. Bicarbonate sits inside the 23–29 mmol/L exam range: in the acute phase it rises only about 1–2 mmol/L per 10 mm Hg increase in pCO₂, because the larger renal compensatory response has not yet developed. B would show low bicarbonate and low pCO₂. C and D don't fit an acidemic pH.
Source: MSD Manual Professional, acid-base compensation table; ASCP BOC MLS content guideline, p. 15: blood-gas ranges.
Q16 · Specimen hemolysis
(MLS-CHM-05)
A potassium of 6.4 mmol/L is obtained on visibly hemolyzed serum from an outpatient with no symptoms and no history of kidney disease. The hemolysis index exceeds the laboratory's validated rejection limit for potassium. What is the best laboratory action?
Answer: D. Withhold the affected result under the laboratory's rejection policy, promptly notify the clinician, and request a new specimen — Red cells hold far more potassium than plasma, so hemolysis during collection or handling releases it and inflates the result. This specimen exceeds the laboratory's rejection limit; notify the clinician and promptly obtain a new specimen according to laboratory policy. Hemolysis does not establish that the patient's potassium is normal. Reporting it as an unaffected result (A) risks treatment based on a false value. Dilution (B) doesn't remove the interference. A mathematical correction (C) is not a substitute for a valid specimen.
Source: MU Health Care, potassium: rejection and notification policy; AHRQ PSNet, Hemolysis Holdup: communication and recollection.
Q17 · Manual dilution
(MLS-CHM-06)
A procedure is validated for this manual dilution: 80 µL of serum mixed with 320 µL of diluent. The diluted specimen measures 38 mg/dL, within the assay's measuring range, and the analyzer has not applied a dilution correction. What is the original specimen's concentration?
Answer: A. 190 mg/dL — Total volume = 80 + 320 = 400 µL. Dilution factor = total volume / sample volume = 400/80 = 5. Original concentration = 38 × 5 = 190 mg/dL. B divides instead of multiplying. C skips the correction. D uses diluent volume instead of total volume, making the factor 4. Always check whether the instrument already applied a factor before you apply one by hand.
Source: CDC/NHANES HDL laboratory procedure, §8.L Dilutions.
Microbiology
Q18 · Staphylococcus identification
(MLS-MIC-01)
A blood culture grows gram-positive cocci in clusters that are catalase positive and tube coagulase positive. What is the most likely identification?
Answer: C. Staphylococcus aureus — Catalase separates staphylococci (positive) from streptococci and enterococci (negative), which rules out B and D. Coagulase then separates S. aureus (positive) from coagulase-negative staphylococci such as S. epidermidis (A). These results are presumptive: coagulase positivity is not unique to S. aureus.
Source: UK SMI ID 7, October 2026: staphylococcal identification; ASM, Coagulase Test: interpretation.
Q19 · Enterococcus identification
(MLS-MIC-02)
Catalase-negative gram-positive cocci in pairs and chains are PYR positive, bile esculin positive, and grow in 6.5% NaCl. What is the most likely identification?
Answer: B. Enterococcus species — Bile esculin hydrolysis plus growth in 6.5% salt, together with PYR positivity, supports a presumptive identification of Enterococcus. Group A strep (A) is also PYR positive but is bile esculin negative. S. pneumoniae (C) is optochin susceptible and bile soluble. Group B strep (D) is PYR negative.
Source: UK SMI ID 4, October 2026: identification table and exceptions; Thermo Fisher streptococcal-grouping instructions: differentiation; Johns Hopkins ABX Guide, Enterococcus: microbiology.
Q20 · Pneumococcus identification
(MLS-MIC-03)
An alpha-hemolytic, catalase-negative gram-positive diplococcus from sputum is optochin susceptible and bile soluble. What is the identification?
Answer: D. Streptococcus pneumoniae — Optochin susceptibility and bile solubility separate pneumococcus from viridans streptococci (A), which are usually optochin resistant. Enterococcus (B) is bile esculin positive and not optochin susceptible. S. agalactiae (C) is usually beta-hemolytic and does not fit this optochin-susceptible, bile-soluble pattern.
Source: UK SMI ID 4, October 2026: identification table and exceptions.
Q21 · Inducible clindamycin resistance
(MLS-MIC-04)
A Staphylococcus aureus isolate tests erythromycin resistant and clindamycin susceptible. In a disk approximation test, the clindamycin zone is flattened next to the erythromycin disk. How should clindamycin be reported?
Answer: C. Resistant (inducible resistance) — The D-shaped zone means erythromycin induced erm-mediated resistance to clindamycin, which can cause treatment failure, so clindamycin is reported resistant. A and D would hide clinically relevant resistance. B is not the interpretation for a positive D-test.
Source: EUCAST v16.1, Staphylococcus table, p. 39: inducible clindamycin resistance; EUCAST expert rules: inducible resistance mechanism and clinical failures.
Q22 · CSF yeast
(MLS-MIC-05)
CSF from a patient with advanced HIV shows encapsulated budding yeast on India ink. The isolate is urease positive. What is the most likely organism?
Answer: A. Cryptococcus neoformans — A prominent capsule, urease activity, and meningitis in an immunocompromised host point to Cryptococcus neoformans. Candida albicans (B) is not encapsulated and is urease negative. Histoplasma (C) is a dimorphic fungus seen as small intracellular yeast in tissue. Aspergillus (D) is a mold with septate hyphae, not a budding yeast.
Source: CDC, Cryptococcosis clinical overview: risk factors and diagnosis; Adelaide Mycology, Cryptococcus: morphology and urease; Thermo Fisher urea-agar instructions, p. 2: Candida interpretation; Adelaide Mycology, histoplasmosis: intracellular yeast; Adelaide Mycology, Aspergillus: mould morphology.
Q23 · Catalase test interference
(MLS-MIC-06)
A technologist performs a slide catalase test on a colony from blood agar. Controls react as expected. Bubbles appear, but the technologist notices a visible piece of blood agar was picked up with the colony. What is the best interpretation and next step?
Answer: D. Repeat without agar carryover, because red-cell catalase can cause a false positive — Red cells contain catalase, so carried-over blood agar can make bubbles on its own. Repeat, picking up only the colony. A ignores the interference. B overstates it: colonies from blood agar can be tested with careful technique. C treats one enzyme test as a species identification. Good controls don't fix a technique problem in an individual test.
Urinalysis and Other Body Fluids
Q24 · Positive blood pad, few RBCs
(MLS-UA-01)
A urine reagent strip shows 3+ blood, but microscopy shows 0–2 RBCs/HPF. The patient's plasma is clear, and serum CK is markedly elevated after a crush injury. What is the most likely cause?
Answer: B. Myoglobinuria — The blood pad detects peroxidase-like activity, and both hemoglobin and myoglobin catalyze it. With few RBCs, a high CK, and clear plasma, myoglobin from muscle injury is the answer. Hemoglobinuria (C) can also make the blood pad positive, but the crush injury and marked CK elevation favor myoglobin. A doesn't fit the clinical picture. Ascorbic acid (D) can cause false negatives on susceptible blood pads, not this strong positive result.
Source: Siemens urinalysis instructions: blood-pad chemistry; AAST rhabdomyolysis consensus: laboratory findings; FDA K181024, p. 15: blood-pad interference.
Q25 · Urine casts
(MLS-UA-02)
Which urine sediment finding most specifically indicates bleeding of glomerular origin?
Answer: C. Red blood cell casts — RBC casts form when red cells enter the tubule and are trapped in a cast matrix, which supports a renal source of bleeding, commonly glomerulonephritis. WBC casts (A) point to renal inflammation such as pyelonephritis or interstitial nephritis. Hyaline casts (B) can be normal in small numbers (0–2/LPF in ASCP's exam ranges). Squamous cells (D) come from the urethra or vagina and do not localize bleeding to the glomerulus.
Source: EFLM Urinalysis Guideline: epithelial cells and casts; ASCP BOC MLS content guideline, p. 17: urine exam ranges.
Immunology
Q26 · Hepatitis B serology
(MLS-IMM-01)
HBsAg positive, IgM anti-HBc positive, anti-HBs negative. What is the interpretation?
Answer: A. Acute hepatitis B infection — HBsAg means current infection, and IgM anti-HBc usually marks a recent one. IgM anti-HBc can also be positive during severe flares or reactivation of chronic hepatitis B. Vaccine immunity (B) shows anti-HBs only. Past infection (C) shows anti-HBs plus total anti-HBc, with HBsAg negative. A susceptible person (D) is negative for HBsAg, total anti-HBc, and anti-HBs.
Q27 · Syphilis serology
(MLS-IMM-02)
A patient with systemic lupus erythematosus has a reactive RPR at 1:2. A treponemal test (TP-PA) is nonreactive. What is the most likely interpretation?
Answer: B. Biologic false-positive nontreponemal result — Nontreponemal tests like RPR detect antibodies to lipoidal antigens, which can show up in autoimmune disease and other conditions. That's why a reactive RPR needs treponemal testing. A reactive nontreponemal result with a nonreactive treponemal test is classified as a biologic false positive (labs may confirm discordance with a second, different treponemal assay). A and D would normally show a reactive treponemal test, and past treated syphilis (C) usually leaves the treponemal test reactive for life.
Source: CDC, Laboratory Recommendations for Syphilis Testing, 2024 (MMWR 73[1]).
Q28 · Prozone effect
(MLS-IMM-03)
A clinician requests a dilution series. An undiluted serum is nonreactive by RPR, but the same specimen becomes reactive after dilution. Controls and technique are correct. Which explanation fits best?
Answer: D. Antibody excess prevented visible lattice formation in the undiluted specimen — This is the prozone effect: excess antibody prevents enough cross-linking to form a visible antigen–antibody lattice, so the undiluted test reads falsely negative. Diluting brings antibody and antigen back into balance. A reverses what dilution does. B changes the assay's identity. C contradicts the antibody-driven reaction. CDC doesn't recommend diluting every nonreactive specimen; prozone checks are done when clinically requested.
Source: CDC, Laboratory Recommendations for Syphilis Testing, 2024 (MMWR 73[1]).
Q29 · Hypersensitivity types
(MLS-IMM-04)
Contact dermatitis from poison ivy that appears 2–3 days after exposure is which hypersensitivity type?
Answer: C. Type IV — Type IV reactions are T-cell mediated and delayed, developing over hours to days; contact dermatitis and the tuberculin skin test are classic examples. Type I (A) is IgE-mediated and immediate. Type II (B) is antibody against cell-surface antigens, such as hemolytic transfusion reactions. Type III (D) is immune-complex disease.
Source: EAACI position paper, §2: hypersensitivity mechanisms; AAAAI/ACAAI contact-dermatitis practice parameter, p. S24; CDC, tuberculin skin test: delayed T-cell response.
Laboratory Operations
Q30 · Westgard rules
(MLS-LO-01)
One control result falls outside the mean ± 3 SD. What does the 1₃ₛ rule require, and what kind of error does it usually reflect?
Answer: D. Reject the run; random error — 1₃ₛ is a rejection rule and usually signals random error. A describes the 1₂ₛ warning rule. Systematic error (B) is classically flagged by rules such as 2₂ₛ and 10ₓ, which catch shifts and trends. C is not how a rejection rule works.
Q31 · Predictive value
(MLS-LO-02)
A new assay is tested in 1,000 patients: 90 true positives, 30 false positives, 10 false negatives, 870 true negatives. What is the positive predictive value?
Answer: A. 75% — PPV = TP / (TP + FP) = 90/120 = 75%. B is sensitivity, 90/(90 + 10). C is specificity, 870/(870 + 30). D is negative predictive value, 870/(870 + 10). Name the denominator before calculating: PPV uses all positive results.
Source: FDA diagnostic-test guidance, §8: predictive values and accuracy measures.
Q32 · Hemocytometer count
(MLS-LO-03)
A 1:20 dilution of blood is loaded on a Neubauer hemocytometer (depth 0.1 mm). A total of 200 WBCs are counted in the four large corner squares (1 mm² each). What is the WBC count?
Answer: B. 10.0 × 10³/µL — Cells/µL = cells counted × dilution / (area counted in mm² × depth in mm) = 200 × 20 / (4 × 0.1) = 4,000/0.4 = 10,000/µL, or 10.0 × 10³/µL. A forgets the 0.1 mm depth. C forgets to divide by the 4 mm² counted. D uses 0.01 mm as the depth.
Source: ZEISS, hemocytometer guide, p. 4: chamber geometry and calculation.
Q33 · Failed QC response
(MLS-LO-04)
A U.S. laboratory runs a nonwaived assay. Today's control results fail the lab's acceptance criteria. Patient results from this run have not been released. Which action meets federal quality requirements?
Answer: D. Hold the run's results, find and fix the cause, and evaluate patient results since the last acceptable control run before reporting — CLIA rules say patient results can't be reported until controls meet acceptance criteria, and when controls fail, the lab must evaluate patient results from the failed run and since the last acceptable run, then take corrective action and document it. Evaluating earlier results doesn't mean automatically cancelling them; it means checking whether they were affected. Normal-looking (A) or repeatable (B) patient values don't prove the system worked. C changes the yardstick to hide the failure.
Source: 42 CFR 493.1256(f)–(g); 42 CFR 493.1282(b)(2).
Check your results
Count your misses in each section, and count any answer you got right but couldn't explain. Those both go in the error log below.
A set this size can point you toward weak spots, but it can't rank your strengths precisely or predict an ASCP score. ASCP doesn't publish any way to convert a practice percentage into its 100–999 scaled score, and two to six items per area is too few to measure much. Treat your result as a list of where to look next.
Your MLS study map
ASCP builds each exam from seven content areas in these official ranges (content guideline, p. 1). The "study first" column is our editorial pick from ASCP's detailed outline, not an official ranking.
| Content area | Share of exam | Study first | Practice here |
|---|---|---|---|
| Blood Banking | 17–22% | ABO/Rh discrepancies; antibody ID with enzyme and DTT effects; Kidd, Duffy, Kell; DAT and transfusion reactions; HDFN and RhIG; component storage and indications | Q6–Q11 |
| Chemistry | 17–22% | Acid-base and electrolytes (anion gap, osmolality); carbohydrates and HbA1c; lipids; proteins, enzymes, cardiac and liver markers; endocrine stimulation/suppression; TDM and toxicology | Q12–Q17 |
| Hematology | 17–22% | Anemia classification by indices; leukemia and lymphoma (WHO), flow cytometry, cytochemistry; hemostasis: PT/aPTT, mixing studies, DIC vs TTP vs HIT, von Willebrand disease | Q1–Q5 |
| Microbiology | 17–22% | Identification by specimen source; rapid tests (catalase, coagulase, oxidase, PYR); susceptibility testing and resistance (ESBL, mecA, vanA, D-test); mycobacteria, fungi, parasites; critical-value reporting | Q18–Q23 |
| Urinalysis and Other Body Fluids | 5–10% | Reagent-strip chemistry and false results; casts and crystals; CSF, synovial, serous, and semen analysis | Q24–Q25 |
| Immunology | 5–10% | Hepatitis and syphilis serology; ANA and autoimmunity; hypersensitivity types; immunodeficiency; monoclonal gammopathies | Q26–Q29 |
| Laboratory Operations | 5–10% | QC rules and failed-QC response; sensitivity, specificity, predictive value; dilutions and molarity; instrumentation principles; safety | Q30–Q33 |
These ranges describe the exam, not how to split your study hours. The four large areas make up most of the test, but the three smaller ones still add up to a meaningful share, so don't skip them.
Must-know calculations
ASCP lists calculations you're expected to know in its content guideline, p. 14. The table covers those calculations and adds anion gap, calculated osmolality, dilutions, and RhIG dosing from the Chemistry, Laboratory Operations, and Blood Banking topics. An on-screen calculator is provided at the exam; you supply the formula.
Use the units shown: the constants in these formulas depend on them. Percentages become fractions when you divide by 100.
| Calculation | Formula and conditions | Worked example |
|---|---|---|
| Corrected WBC | Uncorrected WBC × 100 / (100 + nRBCs per 100 WBC). The starting count must include nRBCs; do not correct an already corrected result. | 15.0 × 100/125 = 12.0 × 10³/µL |
| MCV, MCH, MCHC | Hct × 10 / RBC; Hgb × 10 / RBC; Hgb / Hct × 100. Enter Hct as a percentage number, Hgb in g/dL, and RBC as the numerical count in ×10⁶/µL. | Hct 30, Hgb 9.0, RBC 4.00 → 75 fL, 22.5 pg, 30 g/dL |
| Absolute count from a relative value | (Relative percentage / 100) × total count | Retic (2.0/100) × RBC 4.50 × 10⁶/µL = 90 × 10³/µL |
| Manual hemocytometer count | Cells counted × dilution factor / (area in mm² × chamber depth in mm). This Neubauer example uses a 0.1-mm depth. | 200 × 20 / (4 × 0.1) = 10,000/µL |
| Anion gap | Na − (Cl + HCO₃), all in mmol/L; this version excludes potassium. | 138 − (98 + 12) = 28 mmol/L |
| Calculated serum osmolality | 2Na + glucose/18 + BUN/2.8; Na in mmol/L, glucose and BUN in mg/dL. This is one commonly used estimate. | Na 140, glucose 90, BUN 14 → 280 + 5 + 5 = 290 mOsm/kg |
| LDL (Friedewald) and non-HDL | TC − HDL − TG/5; TC − HDL. All concentrations in mg/dL; use this Friedewald equation only when TG is below 400 mg/dL. | TC 240, HDL 40, TG 200 → LDL 160; non-HDL 200 mg/dL |
| Calculated indirect bilirubin | Total − direct, in the same units | 2.4 − 0.6 = 1.8 mg/dL |
| A/G ratio | Albumin / (total protein − albumin); both concentrations in the same units. The ratio has no units. | Albumin 4.0 and total protein 7.0 g/dL → 4.0/(7.0 − 4.0) = 1.33 |
| % transferrin saturation; UIBC; TIBC | Iron / TIBC × 100; TIBC − iron; iron + UIBC. Use the same concentration units. | Iron 60, TIBC 400 µg/dL → 15%; UIBC 340 µg/dL; 60 + 340 = 400 µg/dL TIBC |
| Timed urine excretion | Amount per collection = concentration (mg/dL) × collected volume (mL) / 100. The collection must be complete and accurately timed. | Urine protein 12 mg/dL × 1,500 mL / 100 = 180 mg in a complete 24-hour collection, or 180 mg/24 h |
| Creatinine clearance | (U × V) / P. U = urine creatinine; P = plasma/serum creatinine in the same concentration units; V = urine flow in mL/min. This gives unindexed mL/min. | U 100 mg/dL, V 1.0 mL/min (1,440 mL/24 h), P 1.0 mg/dL → 100 mL/min |
| Beer's law | A = abc: A = absorbance, a = absorptivity, b = path length, c = concentration. Unknown = (A unknown / A standard) × standard concentration only with blank-corrected absorbances, the same path length and assay conditions, and a linear response. | 0.30 / 0.20 × 100 mg/dL = 150 mg/dL |
| Manual dilution | Uncorrected measured result × (total volume / sample volume), after a validated dilution. Do not apply the factor twice. | 80 µL serum + 320 µL diluent = ×5; 38 → 190 mg/dL |
| RhIG vials (300 µg), using Q9's laboratory rule | Unrounded vials = [(fetal-cell % / 100) × assumed maternal blood volume in mL] / 30. Round to the nearest whole number, with 0.5 upward, then add one. | Assuming 5,000 mL maternal blood: 1.5% → 75 mL fetal whole blood → 2.5 → 3 → 4 vials |
Calculation sources: the related practice questions above explain corrected counts, indices, anion gap, osmolality, LDL, manual dilution, hemocytometer counts, and RhIG. For the other rows, see CDC/NHANES CBC equations, AASLD on calculated indirect bilirubin, CDC on calculated globulin, Corewell's A/G definition, CDC on iron-binding calculations, Labcorp's timed-urine collection and reporting requirements, University Hospitals Birmingham's creatinine-clearance equation, and Agilent's Beer–Lambert explanation, §4.3.
Memorize the reference ranges. ASCP publishes composite chemistry, hematology, urine, CSF, and semen ranges for exam use and says they will not be provided during the exam; other ranges appear when a question needs them. Results show in both conventional and SI units (content guideline, pp. 14–17). These ranges are for the exam only; ASCP notes they aren't meant for clinical use.
Your 4-week MLS review plan
Time assumptions: six 60-minute sessions a week, 24 hours in total, for someone who has finished an MLS program or has MLT-level background. This is our editorial plan, not an ASCP requirement, and four weeks isn't a promise that it'll be enough for everyone.
Each focused review session: 10 minutes of closed-note recall on the last session's topic, 25 minutes of focused review, 15 minutes of practice questions, and 10 minutes to correct misses and log them. A session counts as done when you've produced its output, not when you've read every page. For sessions 1 and 19, use about 50 minutes for the 33 questions and 10 minutes for the tally and initial error-log entries; carry detailed corrections into the following review sessions.
Week 1: Blood Banking and Hematology
| Session | Do this | You finish with |
|---|---|---|
| 1 | Answer all 33 questions above without notes. Tally misses by area and start your error log. | A tally by area and your first error-log entries |
| 2 | Blood Banking I: ABO/Rh typing and discrepancies, antibody screen and ID, enzyme and DTT effects, DAT. Redo Q6 and Q8. | A one-page antigen table: which antigens enzymes destroy, enhance, or leave alone |
| 3 | Blood Banking II: transfusion reactions, HDFN, RhIG dosing, components (storage, expiration, indications). Redo Q7, Q9–Q11. | A reaction table (timing, key lab findings) and two RhIG calculations |
| 4 | Hematology I: anemia classification by indices, RBC morphology, hemoglobinopathies, hemolysis markers. Redo Q1–Q2. | Indices and corrected-WBC calculations worked from memory |
| 5 | Hematology II: WBC disorders, acute and chronic leukemias (WHO), flow cytometry, cytochemistry, BCR::ABL1 and JAK2. Redo Q4. | A comparison of two leukemias you tend to confuse, with the test that separates them |
| 6 | Review: work through the week's error log; drill the hematology reference ranges. | Corrected explanations for every week-1 miss |
Week 2: Hemostasis, Chemistry, and Urinalysis
| Session | Do this | You finish with |
|---|---|---|
| 7 | Hemostasis: PT/aPTT, mixing studies, factor deficiencies and inhibitors, DIC vs TTP vs HIT, von Willebrand disease, anticoagulant monitoring. Redo Q3 and Q5. | A flowchart from abnormal PT/aPTT to the next test |
| 8 | Chemistry I: acid-base, blood gases, electrolytes, osmolality and anion gap. Redo Q12, Q14, Q15. | Three blood gases interpreted with the compensation stated |
| 9 | Chemistry II: carbohydrates and HbA1c, lipids, proteins, renal function and clearance, bilirubin. Redo Q13. | Creatinine clearance, LDL, A/G, and indirect bilirubin worked from memory |
| 10 | Chemistry III: enzymes, cardiac and liver markers, endocrine stimulation/suppression tests, TDM, toxicology. Redo Q16–Q17. | A test → interference → interpretation table for five analytes |
| 11 | Urinalysis and Other Body Fluids: strip chemistry and false results, sediment, CSF, synovial, serous, semen. Redo Q24–Q25. | A list of strip false positives and false negatives by pad |
| 12 | Review: week-2 error log; drill chemistry and body fluid ranges; work the full calculations table. | Every calculation in the table done without looking |
Week 3: Microbiology, Immunology, and Lab Operations
| Session | Do this | You finish with |
|---|---|---|
| 13 | Microbiology I: specimen collection and rejection, stains, blood and CSF cultures, gram-positive cocci (catalase, coagulase, PYR, optochin, bile solubility). Redo Q18–Q20 and Q23. | A gram-positive cocci identification flowchart |
| 14 | Microbiology II: Enterobacterales and nonfermenters, fastidious organisms (Haemophilus X/V, Neisseria), anaerobes, GI, urine, and genital pathogens. | A gram-negative identification flowchart |
| 15 | Microbiology III: susceptibility testing and resistance (ESBL, CRE, mecA, vanA, D-test), select agents and the Laboratory Response Network, critical-value reporting. Redo Q21. | A resistance-mechanism table with the matching lab test |
| 16 | Microbiology IV: mycobacteria, fungi, parasites, viruses. Redo Q22. | A short ID table for the group you know least |
| 17 | Immunology: immune response, hypersensitivity types, autoimmunity and ANA, hepatitis, syphilis (including prozone), EBV and HIV serology, HLA and transplant. Redo Q26–Q29. | Hepatitis B and syphilis interpretation tables written from memory |
| 18 | Laboratory Operations: QC and Westgard rules, failed-QC response, sensitivity/specificity/predictive value, dilutions and molarity, instrumentation, safety. Redo Q30–Q33. | A failed-QC response sequence and a 2×2 table worked both ways |
Week 4: Repair and rehearse
| Session | Do this | You finish with |
|---|---|---|
| 19 | Answer all 33 questions again, cold. Compare misses with session 1. A higher number here partly reflects having seen these items, so focus on what you still can't explain. | An updated weak-area list |
| 20 | Deep review of your weakest area from the error log (or your lowest subtest, if retaking). | Corrected explanations for that area's repeat misses |
| 21 | Deep review of your second-weakest area. | The same, for area two |
| 22 | Timed mixed practice with questions you haven't seen, from any reputable source you already use. Answer in order, flag doubts, and pace at about 90 seconds per question on average. | A pacing note: where you ran slow and why |
| 23 | Drill every ASCP exam reference range in both conventional and SI units, and every calculation in the table using its stated units. | A short list of values still to memorize |
| 24 | Light review only. Reread your ASCP admission notification and Pearson test-day instructions. | A test-day checklist from your official instructions |
Adjust the plan to your time
- 30 minutes a day, six days a week: split each session in two. The same plan takes eight weeks. Keep the practice and correction parts; they're the most useful.
- An irregular schedule: work the sessions in order and ignore the calendar. The numbers matter, not the dates.
- A stubborn weak area: add an extra session on it before moving on. Base that on repeated errors in your log, not on one missed item.
- A closer exam date: cover every area at least once, then spend what's left on your error log. That's prioritizing, not a guarantee the shorter plan is enough.
- Retaking: your failing score report breaks down your performance by subtest (ASCP exam results). Start week 1 with your lowest subtest, then run the plan in order.
Don't drift too long after graduating. A published analysis of first-time MLS and MLT examinees testing in 2013–2014 found lower average scores and pass rates among those who tested 4–12 months after finishing their training program than among those who tested in the first three months (Brown et al., Lab Medicine, 2015). That's an association, not proof that waiting causes failure, but it's a reason to book a date.
Turn a missed question into the next study task
After any miss, or any right answer you couldn't explain, write down what went wrong and the specific task that will fix it. Remembering an answer letter isn't the same as knowing the method.
| Question / topic | What went wrong | The correct rule, in your words | Next task | Recheck on |
|---|---|---|---|---|
| Q17 / manual dilution | I used diluent volume (320) instead of total volume (400). | Factor = (sample + diluent) / sample. | Rework three dilution problems with every volume labeled. | Your next Chemistry session |
| Knowledge gap, misread result, method assumption, units/arithmetic, or misread question |
Explain the corrected rule without looking, then check it again in a later session. If you can only recall the letter, the topic still needs work.
How the ASCP MLS exam works
How many questions, and how long? 100 multiple-choice questions in 2 hours 30 minutes. Each has four options and one best answer (ASCP, About the Examination). That works out to about 90 seconds per question on average; it's arithmetic, not a per-question limit.
What is computer adaptive testing (CAT)? Each correct answer brings a slightly harder question; a miss brings a slightly easier one. Questions from all seven areas are mixed throughout, following the guideline percentages. Some questions are unscored field-test items, and you can't tell which ones.
Can I skip or go back? No skipping: you must answer each question to move on. You can flag questions and review them if time remains after the last one. Changing an earlier answer doesn't change the questions you were already given.
What's the passing score? ASCP reports a scaled score from 100 to 999; 400 is the minimum passing score. That isn't 40% correct, and there's no fixed number or percentage of correct answers that guarantees a pass.
If questions feel hard, am I passing? Feelings about difficulty aren't a result. ASCP also warns that missing questions on purpose to get easier ones tends to backfire by lowering your ability estimate. Answer every question as well as you can.
Is there a calculator? Yes, an on-screen calculator is available on all ASCP BOC certification exams.
When do I get my results? You see a preliminary pass/fail on screen. ASCP emails you within four business days to log in and view your official score report, provided your official transcripts have been received and processed. For score reports and next steps, see our guide to ASCP exam results.
How much does it cost, and can I retake it? The standard MLS application fee is $260, non-refundable, for both MLS(ASCP) and MLS(ASCPi) (ASCP MLS credential page). ASCP lists reduced pricing for applicants educated and residing in low-to-middle income countries. You can take the exam up to five times under one eligibility route while you continue to meet its current requirements; each attempt is a new application and fee, and your new eligibility period starts no earlier than 30 days after your last exam (ASCP, After the Examination). To apply, see ASCP exam registration.
Is MLS(ASCPi) a different exam? Both credentials use the same MLS content guideline and format. The eligibility routes differ (ASCP and ASCPi similarities and differences).
What does ASCP itself offer for prep? The free content guideline and a suggested MLS reading list, which ASCP calls partial and says isn't the only basis for exam questions.
Do I also need a state license? ASCP certification is a national credential, not a license to practice. ASCP is not a licensing authority. Some states license laboratory personnel separately; see our MLS licensure requirements by state and confirm with your state board. Still choosing between credentials? Compare them on medical laboratory certification.
Sources
- ASCP BOC, Medical Laboratory Scientist, MLS(ASCP) and MLS(ASCPi) Examination Content Guideline, revised June 9, 2026: exam model, content areas and ranges (p. 1), outline (pp. 2–13), calculations and exam reference ranges (pp. 14–17).
- ASCP BOC, About the Examination: format, CAT, scoring, calculator, results.
- ASCP BOC, MLS credential page: eligibility routes and fee.
- ASCP BOC, After the Examination: reapplying and attempt limits.
- ASCP BOC, Examination Results: score reports and subtest breakdowns.
- Brown KA, Fenn JP, Freeman VS, Fisher PB, et al. Impact of time lapse on ASCP BOC MLS and MLT examination scores. Lab Med. 2015;46(3):e53–e58.
- Teaching sources for each practice question are linked beneath that question.
Last verified November 1, 2026: ASCP MLS exam format, scoring, fee, retake rules, content-guideline revision, and the source passages supporting the practice explanations and calculation table. The study map and review plan are Castleport's editorial recommendations.
By the Castleport Test Prep Editorial Team.
This page was developed with AI assistance and checked against the sources linked here. Source checking is not professional laboratory review. See how we develop and check resources.
Castleport Test Prep is an independent exam prep publisher. We are not affiliated with, endorsed by, or approved by the American Society for Clinical Pathology (ASCP) or the ASCP Board of Certification. Exam and credential names identify their subjects; trademarks belong to their respective owners. All practice questions are original and unofficial, and no study resource can guarantee a passing score.